Efficacy and Safety of Pozelimab Plus Cemdisiran Vs Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Are Naïve to Complement Inhibition
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-194610
Abstract: Background: Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare, acquired, life-threatening disorder, characterized by hemolysis and an increased risk of thrombosis often co-existing with bone marrow insufficiency. Standard of care includes C5 inhibitors, given as chronic… read more here.
Keywords: treatment; combo; pozelimab; ravu ... See more keywords